359 related articles for article (PubMed ID: 26254811)
1. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
2. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
[TBL] [Abstract][Full Text] [Related]
5. High-dose
Kayano D; Wakabayashi H; Nakajima K; Kuroda R; Watanabe S; Inaki A; Toratani A; Akatani N; Yamase T; Kunita Y; Hiromasa T; Takata A; Mori H; Saito S; Araki R; Taki J; Kinuya S
Ann Nucl Med; 2020 Jun; 34(6):397-406. PubMed ID: 32219730
[TBL] [Abstract][Full Text] [Related]
6. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
7. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
Défachelles AS; Cougnenc O; Carpentier P
Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
[TBL] [Abstract][Full Text] [Related]
8. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
9. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
10. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
11. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
12. Anatomic patterns of relapse and progression following treatment with
Fishel Ben Kenan R; Polishchuk AL; Hawkins RA; Braunstein SE; Matthay KK; DuBois SG; Haas-Kogan DA
Pediatr Blood Cancer; 2022 Feb; 69(2):e29396. PubMed ID: 34662499
[TBL] [Abstract][Full Text] [Related]
13. Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
Anongpornjossakul Y; Sriwatcharin W; Thamnirat K; Chamroonrat W; Kositwattanarerk A; Utamakul C; Sritara C; Chokesuwattanasakul P; Thokanit NS; Pakakasama S; Anurathapan U; Pongphitcha P; Chotipanich C; Hongeng S
Nucl Med Commun; 2020 Apr; 41(4):336-343. PubMed ID: 31939898
[TBL] [Abstract][Full Text] [Related]
14. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
Mastrangelo S; Tornesello A; Diociaiuti L; Riccardi R; Rufini V; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):69-71. PubMed ID: 9002754
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
DuBois SG; Matthay KK
Nucl Med Biol; 2008 Aug; 35 Suppl 1(Suppl 1):S35-48. PubMed ID: 18707633
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
17. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.
Polishchuk AL; Dubois SG; Haas-Kogan D; Hawkins R; Matthay KK
Cancer; 2011 Sep; 117(18):4286-93. PubMed ID: 21387264
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
19. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.
Polishchuk AL; Li R; Hill-Kayser C; Little A; Hawkins RA; Hamilton J; Lau M; Tran HC; Strahlendorf C; Lemons RS; Weinberg V; Matthay KK; DuBois SG; Marcus KJ; Bagatell R; Haas-Kogan DA
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):839-45. PubMed ID: 24867534
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
DuBois SG; Groshen S; Park JR; Haas-Kogan DA; Yang X; Geier E; Chen E; Giacomini K; Weiss B; Cohn SL; Granger MM; Yanik GA; Hawkins R; Courtier J; Jackson H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Villablanca JG; Marachelian A; Matthay KK
Clin Cancer Res; 2015 Jun; 21(12):2715-21. PubMed ID: 25695691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
